Brett Haumann

1.1k total citations
37 papers, 830 citations indexed

About

Brett Haumann is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Surgery. According to data from OpenAlex, Brett Haumann has authored 37 papers receiving a total of 830 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pulmonary and Respiratory Medicine, 25 papers in Physiology and 3 papers in Surgery. Recurrent topics in Brett Haumann's work include Asthma and respiratory diseases (24 papers), Inhalation and Respiratory Drug Delivery (19 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (15 papers). Brett Haumann is often cited by papers focused on Asthma and respiratory diseases (24 papers), Inhalation and Respiratory Drug Delivery (19 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (15 papers). Brett Haumann collaborates with scholars based in United States, United Kingdom and Sweden. Brett Haumann's co-authors include Jan Lötvall, Loretta Jacques, Ashley Woodcock, Eric D. Bateman, Eugene R. Bleecker, Courtney Crim, Angela Davis, Richard Forth, Edmund J. Moran and William W. Busse and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of the American College of Cardiology and CHEST Journal.

In The Last Decade

Brett Haumann

37 papers receiving 819 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Brett Haumann United States	17	728	673	55	34	32	37	830
J.J. Smeets Netherlands	9	609 0.8×	543 0.8×	18 0.3×	32 0.9×	22 0.7×	16	673
Anna Unseld Germany	9	297 0.4×	371 0.6×	9 0.2×	5 0.1×	59 1.8×	19	499
Y Salorinne Finland	12	230 0.3×	159 0.2×	64 1.2×	38 1.1×	61 1.9×	25	481
Benjamı́n Sarriá Spain	13	167 0.2×	241 0.4×	32 0.6×	10 0.3×	128 4.0×	30	480
R. Townley United States	7	245 0.3×	275 0.4×	8 0.1×	8 0.2×	38 1.2×	16	348
Leandro Genehr Fritscher Brazil	11	188 0.3×	225 0.3×	31 0.6×	1 0.0×	29 0.9×	20	426
Natalia Celejewska‐Wójcik Poland	12	157 0.2×	205 0.3×	18 0.3×	1 0.0×	13 0.4×	31	311
David Muccino United States	11	408 0.6×	352 0.5×	9 0.2×		17 0.5×	28	481
Thomas M. Siler United States	10	501 0.7×	381 0.6×	14 0.3×	2 0.1×	31 1.0×	24	549
Joseph Aumann Belgium	10	490 0.7×	407 0.6×	21 0.4×	2 0.1×	15 0.5×	18	523

Countries citing papers authored by Brett Haumann

Since Specialization

Citations

This map shows the geographic impact of Brett Haumann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brett Haumann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brett Haumann more than expected).

Fields of papers citing papers by Brett Haumann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brett Haumann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brett Haumann. The network helps show where Brett Haumann may publish in the future.

Co-authorship network of co-authors of Brett Haumann

This figure shows the co-authorship network connecting the top 25 collaborators of Brett Haumann. A scholar is included among the top collaborators of Brett Haumann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brett Haumann. Brett Haumann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Belperio, John A., Tuan S. Nguyen, David A. Lombardi, et al.. (2023). Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial. BMJ Open Respiratory Research. 10(1). e001627–e001627. 5 indexed citations

Kaufmann, Horacio, Ross G. Vickery, Whedy Wang, et al.. (2021). Safety and efficacy of ampreloxetine in symptomatic neurogenic orthostatic hypotension: a phase 2 trial. Clinical Autonomic Research. 31(6). 699–711. 16 indexed citations

Donohue, James F., et al.. (2020). Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis. BMC Pulmonary Medicine. 20(1). 134–134. 3 indexed citations

Raj, Satish R., Lucy Norcliffe‐Kaufmann, Whedy Wang, Brett Haumann, & Ross G. Vickery. (2020). HEMODYNAMIC EFFECTS AND CARDIOVASCULAR SAFETY OF ONCE-DAILY ORAL AMPRELOXETINE (TD-9855), A NOREPINEPHRINE REUPTAKE INHIBITOR, IN HEALTHY ADULTS AND SUBJECTS WITH SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION. Journal of the American College of Cardiology. 75(11). 333–333. 1 indexed citations

Donohue, James F., Edward Kerwin, Sanjay Sethi, et al.. (2019). Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease. Respiratory Medicine. 153. 38–43. 26 indexed citations

Ferguson, Gary T., Gregory Feldman, Chris N. Barnes, et al.. (2019). Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical Trials. Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation. 6(2). 154–165. 23 indexed citations

Donohue, James F., Edward Kerwin, Sanjay Sethi, et al.. (2019). Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease. SHILAP Revista de lepidopterología. 26. 104277–104277. 1 indexed citations

Quinn, Dean, Christopher Barnes, David L. Bourdet, et al.. (2017). Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies. Pulmonary Pharmacology & Therapeutics. 48. 71–79. 31 indexed citations

Bourdet, David L., et al.. (2014). Repeated-dose pharmacokinetics of once-daily TD-4208, a long-acting muscarinic receptor antagonist (LAMA), in subjects with COPD. European Respiratory Journal. 44(Suppl 58). 1892–1892. 1 indexed citations

10.

Bateman, Eric D., Eugene R. Bleecker, Jan Lötvall, et al.. (2012). Dose effect of once-daily fluticasone furoate in persistent asthma: A randomized trial. Respiratory Medicine. 106(5). 642–650. 57 indexed citations

11.

Hanania, Nicola A., Gregory Feldman, Jae-Jeong Shim, et al.. (2012). The Efficacy and Safety of the Novel Long-Acting β2 Agonist Vilanterol in Patients With COPD. CHEST Journal. 142(1). 119–127. 83 indexed citations

12.

Bleecker, Eugene R., Eric D. Bateman, Ashley Woodcock, et al.. (2012). Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. Annals of Allergy Asthma & Immunology. 109(5). 353–358.e4. 45 indexed citations

13.

Lötvall, Jan, Eric D. Bateman, Eugene R. Bleecker, et al.. (2012). 24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids. European Respiratory Journal. 40(3). 570–579. 61 indexed citations

14.

Sterling, Richard K., et al.. (2012). Efficacy and optimal dosing interval of the long-acting beta2 agonist, vilanterol, in persistent asthma: A randomised trial. Respiratory Medicine. 106(8). 1110–1115. 24 indexed citations

15.

Vestbo, Jørgen, Julie A. Anderson, Robert D. Brook, et al.. (2012). The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. European Respiratory Journal. 41(5). 1017–1022. 67 indexed citations

16.

Woodcock, Ashley, Eugene R. Bleecker, Jan Lötvall, et al.. (2011). Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma. Respiratory Research. 12(1). 160–160. 38 indexed citations

17.

Busse, William W., Eugene R. Bleecker, Eric D. Bateman, et al.. (2011). Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Thorax. 67(1). 35–41. 67 indexed citations

18.

Lötvall, Jan, Eric D. Bateman, Eugene R. Bleecker, et al.. (2011). Four Weeks' Treatment With The Novel Long-Acting Beta2 Agonist (LABA) Vilanterol Trifenatate (VI) In Asthma - Evaluation Of Safety And Maintained Efficacy Of Albuterol. A4491–A4491. 2 indexed citations

19.

Rimmer, Janet, Philip G. Bardin, Richard A. Robson, et al.. (2006). Targeting adenosine receptors in the treatment of allergic rhinitis: a randomized, double‐blind, placebo‐controlled study. Clinical & Experimental Allergy. 37(1). 8–14. 24 indexed citations

20.

Coyle, Michael, D. Barry Keenan, Linda S. Henderson, et al.. (2005). Evaluation of an ambulatory system for the quantification of cough frequency in patients with chronic obstructive pulmonary disease. PubMed. 1(1). 3–3. 97 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact